RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 901–1,000 of 1,003
MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma
Sun, L., Chua, C. Y. X., Tian, W., Zhang, Z., Chiao, P. J., & Zhang, W. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.07.003 · Cited by 20
Osumi, H., Ishizuka, N., Takashima, A., Kumekawa, Y., Nakano, D., Shiozawa, M., Denda, T., Sawada, R., Ouchi, K., Wakatsuki, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063071 · Cited by 19
The discovery of novel imidazo[1,2- a ]pyridine derivatives as covalent anticancer agents
Song, Q., Zhang, Q., Fan, X., Kayaat, F., Lv, R., Li, J., & Wang, Y. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00694a · Cited by 19
PLCɛ and the RASSF family in tumour suppression and other functions
Chan, J. J., & Katan, M. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.07.008 · Cited by 25
Doğan, İ., Ozkan, A. C., & Ekmekçi, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-3671-0 · Cited by 20
Resistance of R-Ras knockout mice to skin tumour induction
May, U., Prince, S., Vähätupa, M., Laitinen, A. M., Nieminen, K., Uusitalo‐Järvinen, H., & Järvinen, T. A. H. (2015) · Scientific Reports · doi:10.1038/srep11663 · Cited by 19
Dolgikh, N., Hugle, M., Vogler, M., & Fulda, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1737 · Cited by 23
Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer
Shifteh, D., Sapir, T., Pahmer, M., Haimowitz, A., Goel, S., & Maitra, R. (2020) · Cancers · doi:10.3390/cancers12082091 · Cited by 21
KRAS mutations are negatively correlated with immunity in colon cancer
Fu, X., Wang, X., Duanmu, J., Li, T., & Jiang, Q. (2020) · Aging · doi:10.18632/aging.202182 · Cited by 20
“The contribution of RAS to anti-apoptosis, proliferation, and metastasis ability of cancer cells has been well validated [32, 33].”
BackgroundRas Signaling in Breast Cancer
Moon, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_4 · Cited by 25
Modified natriuretic peptides and their potential roles in cancer treatment
Xu, M., Liu, X., Li, P., Yang, Y., Zhang, W., Zhao, S., Zeng, Y., Zhou, X., Zeng, L., & Yang, G. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.06.007 · Cited by 25
Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis
Liu, C., Mo, L., Feng, B., Jin, Q., Li, Y., Lin, J., Shu, Q., Liu, Z.-G., Liu, Z., Sun, X., et al. (2021) · Theranostics · doi:10.7150/thno.62256 · Cited by 19
“Ras is involved in the signal transduction pathways of multiple cell activities, one of which is to sustain relevant cell activities, such as cancer cell overgrowth [14].”
BackgroundAddressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling
Marín‐Ramos, N. I., Piñar, C., Vázquez‐Villa, H., Martín‐Fontecha, M., González, Á., Canales, Á., Algar, S., Mayo, P. P., Jiménez‐Barbero, J., Gajate, C., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604905 · Cited by 19
Shimizu, M., Shibuya, H., & Tanaka, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-06916-y · Cited by 18
Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science · doi:10.1111/cas.12383 · Cited by 18
Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer
Moraca, F., Arciuolo, V., Marzano, S., Napolitano, F., Castellano, G., D’Aria, F., Porzio, A. D., Landolfi, L., Catalanotti, B., Randazzo, A., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117245 · Cited by 19
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 23
Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
Liu, Y., Cheng, Y., Huang, G., Xia, X., Wang, X., & Tian, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1271268 · Cited by 19
“In this pathway, activated RAF phosphorylates and activates MEK1 (mitogen-activated protein kinase kinase) and MEK2 kinases, leading to downstream phosphorylation and activation of extracellular signal-regulated kinases, ERK1 and ERK2, which in turn triggers downstream activation of nuclear and cytoplasmic targets ass…”
Pharmacological Inhibition of Protein Lipidation
Ganesan, L., & Levental, I. (2015) · The Journal of Membrane Biology · doi:10.1007/s00232-015-9835-4 · Cited by 20
The drs tumor suppressor regulates glucose metabolism via lactate dehydrogenase‐B
Tambe, Y., Hasebe, M., Kim, C. J., Yamamoto, A., & Inoue, H. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22258 · Cited by 21
“K-ras mutations have been frequently reported in human colorectal and lung cancers [43,44].”
BackgroundCheng, D., Zhao, L., Xu, Y., Ou, R., Li, G., Yang, H., & Li, W. (2015) · Tumor Biology · doi:10.1007/s13277-015-3429-8 · Cited by 19
“to a wide array of downstream effectors by alternating conformation between GTP-bound and GDP-bound status [9, 10].”
BackgroundRUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
Lee, J.-W., van Wijnen, A. J., & Bae, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_20 · Cited by 21
Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting
Michael, J. V., & Goldfinger, L. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.021 · Cited by 19
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 19
Pillonel, V., Juškevičius, D., Bihl, M., Stenner, F., Halter, J. P., Dirnhofer, S., & Tzankov, A. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1786560 · Cited by 17
Relaxed initiation pausing of ribosomes drives oncogenic translation
Dong, L., Mao, Y., Zhou, A., Liu, X., Zhou, J. L., Wan, J., & Qian, S. (2021) · Science Advances · doi:10.1126/sciadv.abd6927 · Cited by 18
Rahmani, F., Hashemzehi, M., Avan, A., Barneh, F., Asgharzadeh, F., Marjaneh, R. M., Soleimani, A., Parizadeh, M., Ferns, G. A., Mobarhan, M. G., et al. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110069 · Cited by 18
Yang, Y., Gao, L., Weng, N., Li, J., Liu, J. L., Zhou, Y., Liao, R., Xiong, Q., Xu, Y., Varela-Ramírez, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708900 · Cited by 18
Targeting long non coding RNA by natural products: Implications for cancer therapy
Homayoonfal, M., Asemi, Z., & Yousefi, B. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.2001785 · Cited by 19
“The Oncogenic activity of RASs as a consequence of their mutation has been discovered in different types of cancer (Pylayeva-Gupta, Grabocka, and Bar-Sagi 2011).”
BackgroundPoloznikov, A. A., Nikulin, S. V., Болотина, Л. В., Качмазов, А. А., Raigorodskaya, M. P., Kudryavtseva, A. V., Bakhtogarimov, I. R., Rodin, S., Gaisina, I. N., Topchiy, M. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777114 · Cited by 18
“Notably, the KRAS gene frequently mutates in other cancers, such as pancreatic and lung, and is associated with poor prognosis, increased tumor aggressiveness and metastasis, and resistance to chemotherapy and targeted therapies (Slebos et al., 1990; Hanahan andWeinberg, 2011; Pylayeva-Gupta et al., 2011).”
BackgroundDescarpentrie, J., Araúzo-Bravo, M. J., He, Z., François, A., González, Á., García-Gallastegui, P., Badiola, I., Évrard, S., Pernot, S., Creemers, J. W. M., et al. (2022) · Cancers · doi:10.3390/cancers14051195 · Cited by 18
Shaw, H. M., & Nathan, P. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.24 · Cited by 18
Wild-type Kras expands and exhausts hematopoietic stem cells
Sasine, J. P., Himburg, H. A., Termini, C. M., Roos, M. M., Tran, E., Zhao, L., Kan, J., Li, M., Zhang, Y., de Barros, S. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98197 · Cited by 18
Yang, W., Meng, L., Chen, K., Tian, C., Peng, B., Zhong, L., Zhang, C., Yang, X., Zou, J., Yang, S., et al. (2019) · Cancer Science · doi:10.1111/cas.13929 · Cited by 18
Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice
Salaymeh, Y., Farago, M., Sebban, S., Shalom, B., Pikarsky, E., & Katzav, S. (2020) · Life Science Alliance · doi:10.26508/lsa.202000661 · Cited by 18
“…its progression to invasive PDAC suggests that disease progression requires additional genetic and epigenetic aberrations, such as in fl ammation and/or additional molecular insults (Hingorani & Tuveson, 2003; Guerra et al, 2007; Seidler et al, 2008; Morris et al, 2010; Pylayeva-Gupta et al, 2011).”
Kazi, A., Ranjan, A., Vasantha Kumar, M. V., Agianian, B., Chavez, M. G., Vudatha, V., Wang, R., Vangipurapu, R., Chen, L., Kennedy, P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0222 · Cited by 17
Taylor, R. D., Chandran, A., Kashiwazaki, G., Hashiya, K., Bando, T., Nagase, H., & Sugiyama, H. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201501870 · Cited by 17
β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients
Schirosi, L., Mazzotta, A., Opinto, G., Pinto, R., Graziano, G., Tommasi, S., Fucci, L., Simone, G., & Mangia, A. (2016) · Oncotarget · doi:10.18632/oncotarget.12280 · Cited by 17
The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
Wan, X., Liu, R., & Li, Z. (2017) · BioMed Research International · doi:10.1155/2017/5356737 · Cited by 17
Ray, M., & Lakhotia, S. C. (2019) · Developmental Dynamics · doi:10.1002/dvdy.102 · Cited by 17
“Since activated Ras is also implicated in various cancers (Karim and Rubin, 1998; Prober and Edgar, 2000; Fernández-Medarde and Santos, 2011; Pylayeva-Gupta et al., 2011), the present finding of the activated Ras dependent long-range inter-organ signaling has implications for disease conditions as well.”
BackgroundBilling, O., Holmgren, Y., Nosek, D., Hedman, H., & Hemmingsson, O. (2021) · Oncogene · doi:10.1038/s41388-021-01808-3 · Cited by 17
“Human cancers are frequently driven by activating mutations in RAS [1] or RAF [2] genes or in upstream receptor tyrosine kinases (RTKs) [3].”
BackgroundKRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
Wang, S., Li, Q., Ma, P., Fang, Y., Yu, Y., Jiang, N., Miao, H., Tang, Q., Yang, Y., Xing, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.831382 · Cited by 18
“9:831382. doi: 10.3389/fmolb.2022.831382 Abbreviations:NSCLC, non-small-cell lung cancer; NGS, next-generation sequencing; TMB, tumour mutational burden; MSI, microsatellite instability; PD-L1, programmed cell death ligand-1; FFPE, formalin fixed paraffin embedded; IHC, immunohistochemistry; CUP, cancer of unknown pri…”
BackgroundInfluentialA rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
Ocal, O., Pashkov, V., Kollipara, R. K., Zolghadri, Y., Cruz, V. H., Hale, M. A., Heath, B. R., Artyukhin, A. B., Christie, A. L., Tsoulfas, P., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.020933 · Cited by 21
“Kras) (Pylayeva-Gupta et al., 2011).”
Melloni, G. E. M., de Pretis, S., Riva, L., Pelizzola, M., Ceol, A. G. M., Costanza, J., Müller, H., & Zammataro, L. A. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0935-7 · Cited by 18
“Second, we performed the same analysis dividing the mutations by the four main subfamilies: 1) Ras subfamily, involved in cell proliferation [26], 2) Rheb subfamily, involved in neural plasticity [27], 3) Rho subfamily, involved in cytoskeletal morphology [28] and 4) Rab family, involved in cell…”
MethodPantaleoni, F., Lev, D., Cirstea, I. C., Motta, M., Lepri, F. R., Bottero, L., Cecchetti, S., Linger, I., Paolacci, S., Flex, E., et al. (2017) · Human Mutation · doi:10.1002/humu.23224 · Cited by 17
An Orthosteric Inhibitor of the RAS–SOS Interaction
Nickerson, S., Joy, S. T., Arora, P. S., & Bar‐Sagi, D. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00002-0 · Cited by 17
Self-citationThabet, N. A., El-Guendy, N., Mohamed, M. M., & Shouman, S. A. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114773 · Cited by 17
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N., & Katayama, R. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00793-6 · Cited by 16
Li, M., Dai, L.-T., Gao, Z.-Y., Yan, J.-T., Xu, S., Tan, J., Huang, Z., Chen, S.-B., & Chen, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01773 · Cited by 17
Hong, P., Xu, T., Xu, J., Chen, W., Xu, J., Chen, J., Li, L., Zheng, C., Li, L., Liu, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216994 · Cited by 17
Sacco, E., Spinelli, M., & Vanoni, M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.728586 · Cited by 17
“Furthermore, specific RAS genes are mutated in different malignancies: K-RAS mutations are prevalent in pancreatic, colorectal, endometrial, biliary tract, lung and ovarian cancers; K-RAS and N-RAS mutations are found in malignancies of hematopoietic and lymphoid tissue; N-RAS and H-RAS mutations predominate in melano…”
Water Distribution within Wild-Type NRas Protein and Q61 Mutants during Unrestrained QM/MM Dynamics
Tichauer, R. H., Favre, G., Cabantous, S., Landa, G., Hémeryck, A., & Brut, M. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.07.042 · Cited by 16
Alcantara, K. M. M., Malapit, J. R. P., Yu, R. T. D., Garrido, J. A. M. G., Rigor, J. P. T., Angeles, A. K., la Paz, E. M. C., & Garcia, R. L. (2019) · Cells · doi:10.3390/cells8121557 · Cited by 16
Xiao, H., Zha, C., Shao, F., Wang, L., & Tan, B. (2020) · Animal nutrition · doi:10.1016/j.aninu.2019.12.001 · Cited by 16
“, 2016); 2) key mechanisms of signaling pathways, c-Myc, phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)/Akt/mTOR, p53 and K-Rasmitogen-activated protein kinase (MAPK) signaling pathways (Morita et al., 2015; Li et al., 2005; Pylayeva-Gupta et al., 2011; Vyas et al., 2016).”
BackgroundAmanlou, M., Hashemi, S., Sharifi, A., Zareei, S., Mohamedi, G., & Biglar, M. (2020) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.288425 · Cited by 17
“We focused on the mutation on G12 residue (KRAS) which suppresses GAP-induced GTP hydrolysis (23) and makes the protein constitutively inactive form.”
BackgroundOrigin of Genome Instability and Determinants of Mutational Landscape in Cancer Cells
Mehrotra, S., & Mittra, I. (2020) · Genes · doi:10.3390/genes11091101 · Cited by 19
Lopes, E. C., Dias, M. H., da Silva, M. S., Zeidler, J. D., Vessoni, A. T., Reis, M. S., Boccardo, E., & Armelin, H. A. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03476-3 · Cited by 16
Lee, S. J., Yoo, S. Y., Kang, D., Lee, K. J., Ha, T. H., Wee, W., Lee, A.-R., Kim, N. S., & Kwon, J. S. (2008) · Psychopathology · doi:10.1159/000125557 · Cited by 16
Bao, X.-H., Takaoka, M., Hao, H., Wang, Z., Fukazawa, T., Yamatsuji, T., Sakurama, K., Sun, D. S., Nagasaka, T., Fujiwara, T., et al. (2012) · PubMed · Cited by 16
Liao, J., Hwang, S. H., Li, H., Liu, J., Hammock, B. D., & Yang, G. Y. (2016) · PubMed · Cited by 18
Cabezón, V., Vialás, V., Gil-Bona, A., Reales‐Calderón, J. A., Martínez-Gomáriz, M., Gutiérrez-Blázquez, D., Monteoliva, L., Molero, G., Ramsdale, M., & Gil, C. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00913 · Cited by 17
From phenologs to silent suppressors: Identifying potential therapeutic targets for human disease
Golden, A. (2017) · Molecular Reproduction and Development · doi:10.1002/mrd.22880 · Cited by 16
“Mutations in any of the three RAS proto-oncogenes are thought to be a common occurrence in most types of human cancers (Pylayeva-Gupta et al., 2011).”
BackgroundRAS pathway biomarkers for breast cancer prognosis.
van Reesema, L. L. S., Lee, M. P., Zheleva, V. P., Winston, J. S., O'Connor, C. F., Perry, R. R., Hoefer, R. A., & Tang, A. (2016) · PubMed · Cited by 16
ERF deletion rescues RAS deficiency in mouse embryonic stem cells
Mayor‐Ruiz, C., Olbrich, T., Drosten, M., Lecona, E., Vega-Sendino, M., Ortega, S., Domínguez, O., Barbacid, M., Ruiz, S., & Fernández-Capetillo, Ó. (2018) · Genes & Development · doi:10.1101/gad.310086.117 · Cited by 17
“Besides their role in pluripotency, RAS genes are best known as the most frequently mutated human oncogene (Pylayeva-Gupta et al. 2011).”
BackgroundYoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02727-2 · Cited by 15
“Considerable efforts have been dedicated to exploring alternative strategies for the treatment of KRAS-mutated cancers, with a focus on inhibiting downstream signalling within the mitogen-activated protein kinase (MAPK; RAF/MEK/ERK) pathway [7].”
Zhang, Z., Wang, X., Ye, J., Liu, H., Fang, J., Zhang, M., Li, Y., Huang, J., Zhang, D., Wang, J., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00426 · Cited by 15
Peralta, S., Duhamel, G. E., Katt, W. P., Heikinheimo, K., Miller, A. D., Ahmed, F., McCleary‐Wheeler, A. L., & Grenier, J. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97430-0 · Cited by 17
Zheng, Z.-Y., Elsarraj, H. S., Lei, J. T., Yan, H., Anurag, M., Long, F., Kennedy, H., Shen, Y., Lo, F., Zhao, Z., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01565-5 · Cited by 19
“Oncogenic RAS mutations, which lock the RAS proteins in the GTPbound state, can be found in approximately 30% of human cancers [13]; however, RAS oncogenic mutations are very rare in primary breast cancer [14].”
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 18
“Mutations in the RAS family lead to constitutive activation of RAS signaling pathways (RAS/RAF/MEK/ERK and RAS/PI3K/AKT), resulting in autonomous signal propagation independent of extrinsic ligands (10).”
RAS Pathway Mutations and Therapeutics in Vascular Anomalies
Alharbi, S., Merkle, S., Hammill, A. M., Waters, A. M., & Cras, T. D. L. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31605 · Cited by 15
“RAS proteins control cell cycle progression, differentiation, survival, actin cytoskeleton, polarity, movement, and nuclear transport [6, 7].”
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective
Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608270 · Cited by 14
Targeting Mutant KRAS for Anticancer Therapy
Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15
Kobayashi, T., Miyazaki, M., Sasaki, N., Yamamuro, S., Uchida, E., Kawauchi, D., Takahashi, M., Otsuka, Y., Kumagai, K., Takeuchi, S., et al. (2020) · Cancers · doi:10.3390/cancers12123641 · Cited by 16
Sad, K., Parashar, P., Tripathi, P., Hungyo, H., Sistla, R. K., Soni, R., & Tandon, V. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.11.001 · Cited by 15
Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition
Wang, X., Kim, C., Zhang, Y., Rindhe, S., Cobb, M. H., & Yu, Y. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00550 · Cited by 15
Pathogenic signaling in multiple myeloma
Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 15
Lu, H., & Martí, J. (2022) · Nanoscale · doi:10.1039/d1nr07622a · Cited by 15
Shai, A., Galouk, E., Miari, R., Tareef, H., Sammar, M., Zeidan, M., Rayan, A., & Falah, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13250 · Cited by 15
“Such mutations have been implicated in the pathogenesis of numerous cancers, including approximately 97% of pancreatic ductal adenocarcinoma, 52% of colorectal adenocarcinomas, 32% of lung adenocarcinomas (1,3,4), and lower percentages of other cancers (5,6).”
BackgroundAlternative polyadenylation is a determinant of oncogenic Ras function
Subramanian, A., Hall, M., Hou, H., Mufteev, M., Yu, B., Yuki, K. E., Nishimura, H., Sathaseevan, A., Lant, B., Zhai, B., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh0562 · Cited by 17
Base excision repair accessory factors in senescence avoidance and resistance to treatments
Vickridge, E., Faraco, C. C. F., & Nepveu, A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.36 · Cited by 16
Nakhaei‐Rad, S., Nakhaeizadeh, H., Kordes, C., Cirstea, I. C., Schmick, M., Dvorský, R., Bastiaens, P. I. H., Häussinger, D., & Ahmadian, M. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.640607 · Cited by 16
Conti, A., Majorini, M. T., Elliott, R. J. R., Ashworth, A., Lord, C. J., Cancelliere, C., Bardelli, A., Seneci, P., Walczak, H., Delia, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3552 · Cited by 16
“RAS proteins require GTP to be activated and undergo rapid cycles of activation and inactivation crucial for physiological signaling [1].”
BackgroundA Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Dvorkina, M., Nieddu, V., Chakelam, S., Pezzolo, A., Cantilena, S., Leite, A. P., Chayka, O., Regad, T., Pistorio, A., Sementa, A. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2081 · Cited by 16
“In this respect, as oncogenic RAS is known to inhibit the expression of TSP2 in tumor cells (43), it could be hypothesized that TSP2 induction could be part of a PML/pRb tumor-suppressive checkpoint triggered by RAS activation in normal cells (44).”
Carlson, J. A., Xavier‐Júnior, J. C. C., Tarasen, A. J., Sheehan, C. E., Otto, G. A., Miller, V. A., Stephens, P. J., Elvin, J. A., Vergilio, J., Suh, J. H., et al. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000729 · Cited by 16
“Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways.(54) NRAS mutations have been reported in 20% of melanoma cases (7%–33% in various studies), with similar frequency in primary and metastatic samples and mutations most often affecting…”
BackgroundLubeseder–Martellato, C., Alexandrow, K., Hidalgo‐Sastre, A., Heid, I., Boos, S. L., von Briel, T., Schmid, R. M., & Siveke, J. T. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.013 · Cited by 16
Tumor-augmenting effects of gestational arsenic exposure on F1 and F2 in mice
Nohara, K., Suzuki, T., Okamura, K., Matsushita, J., & Takumi, S. (2017) · Genes and Environment · doi:10.1186/s41021-016-0069-1 · Cited by 16
“Ha-ras mutation Several types of cancers in humans and mice frequently contain mutation of the ras oncogene family (Ha-, Ki-, and N-ras), which keeps the protein in the active form and is thought to be an early event occurring in the initiation stage and in driving tumorigenesis in various processes [19, 43].”
BackgroundPharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Ruess, D. A., Görgülü, K., Wörmann, S. M., & Algül, H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0453-y · Cited by 15
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers
Dai, X., Xia, H., Zhou, S., Tang, Q., & Bi, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.022 · Cited by 17
Chang, Y., Hsu, C., Tang, C.-W., Chen, X., Huang, H., & Juan, H. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002219 · Cited by 15
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
Toward the Goal of Personalized Therapy in Pancreatic Cancer by Targeting the Molecular Phenotype
Yee, N. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_5 · Cited by 15
Extracellular CD44 lactylation impairs CD8+ T cell function in KRAS-mutant colorectal cancer
Yang, Y., Wu, Y., Guo, X., Gan, W.-J., Wu, W.-X., Shi, W.-Y., He, X., Liu, Y.-X., Wan, S., Jiang, Z., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01482-3 · Cited by 14
Cui, J., Jiang, K., Li, W., Ni, S., Zong, H., Du, J., He, Y., Liu, Z., Kong, G., Zhang, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04538-9 · Cited by 16
“…events occurred in 11 patients (36.7%); the median PFS was 13.1 months (95% CI = 12.0 to not reached), with PFS rates of 89.4% (95% driver mutation locks the KRAS in a constantly active state, promoting uncontrolled proliferation, enhancing survival and driving metastatic progression 10,14,15 .”
InfluentialTeam work and cytopathology molecular diagnosis of solid pancreatic lesions
Fabbri, C., Gibiino, G., Fornelli, A., Cennamo, V., Grifoni, D., Visani, M., Acquaviva, G., Fassan, M., Fiorino, S., Giovanelli, S., et al. (2017) · Digestive Endoscopy · doi:10.1111/den.12845 · Cited by 14
Current progress of pig models for liver cancer research
Wang, L., Piao, Y., Guo, F., Wei, J., Chen, Y., Dai, X., & Zhang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115256 · Cited by 18
Vagaja, N., Parry, J., McCallum, D., Thomas, M., & Bentel, J. M. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202969 · Cited by 16
Comparison of liver oncogenic potential among human RAS isoforms
Chung, S. I., Moon, H., Ju, H.-L., Kim, D. Y., Cho, K. J., Ribback, S., Dombrowski, F., Calvisi, D. F., & Ro, S. W. (2016) · Oncotarget · doi:10.18632/oncotarget.6931 · Cited by 14
“These mutations, resulting in unrestrained RAS activity, lead to the sustained activation of diverse signaling pathways involved in carcinogenesis [2].”
BackgroundComparative mutational landscape analysis of patient-derived tumour xenografts
Brait, M., Izumchenko, E., Kagohara, L. T., Long, S., Wysocki, P., Faherty, B., Fertig, E. J., Khor, T. O., Bruckheimer, E. M., Baía, G. S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.450 · Cited by 14
“KRAS and BRAF mutations are usually associated with poor prognosis and chemotherapeutic resistance in various solid malignancies (Davies et al, 2002; Pylayeva-Gupta et al, 2011).”
Background
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.